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Abstract: Proper management of diabetes requires the frequent 
measurement of a patient’s blood glucose level. To create a long-term, 
minimally-invasive sensor that is sensitive to physiological concentrations 
of glucose a fluorescent glucose sensing assay using a competitive binding 
approach between fluorescently tagged Concanavalin-A (Con-A) and 
glycodendrimer is being developed. Until now, the essential step of 
effectively encapsulating this aggregative sensing assay while allowing a 
reversible response has yet to be reported. In this paper, a microporation 
technique is described in which microspheres are synthesized in a manner 
that creates fluid-filled pores within a poly (ethylene glycol) hydrogel. This 
dual-nature technique creates hydrophilic, biocompatible microcapsules in 
which the aggregative binding kinetics of the sensing assay within the pores 
are not constrained by spatial fixation in the hydrogel matrix. Confocal 
images displaying the localization of pockets filled with the assay within the 
polymeric matrix are presented in this paper. In addition, fluorescent 
responses to varying glucose concentrations, leaching studies, and long-term 
functionality of the encapsulated assay are demonstrated. To our 
knowledge, this is the first time that the Con-A/glycodendrimer assay has 
been shown to be reversible and repeatable within hydrogel spheres, 
including the display of functionality up to fourteen days under ambient 
conditions. 
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1. Introduction 
Diabetes mellitus is a chronic disease where the body is unable to regulate its blood glucose 
concentration within normal physiological levels leading to secondary complications such as 
retinopathy, neuropathy, nephropathy, and cardiovascular disease [1,2] As of 2007, 17 million 
individuals in America lived with the disease, resulting in an economic burden totaling over 
110 billion dollars in direct medical costs [3]. Proper management aims to improve diabetic 
outcomes by maintaining blood glucose levels within normal concentrations which typically 
includes an effective diet, exercise, and glucose monitoring program [1,4]. The effectiveness 
of diabetic management has been described by A1C values (glycated hemoglobin), an 
indicator of the mean glucose levels over several months [4,5]. While the most common 
method for monitoring blood glucose is the typical finger-stick approach [6], systems that 
allow for more-frequent sensing have been shown to be more effective in maintaining normal 
A1C values in adults. Therefore, the thrust of glucose sensing has been to develop a 
repeatable, long-lasting technique that can be used to maintain normal A1C levels while also 
increasing patient compliance. These A1C levels indicate the amount of hemoglobin that is 
glycated, which corresponds to the average glucose concentration in the plasma over several 
months [7]. 
The field of glucose-sensing as a whole has been widely explored and finely detailed by 
several groups [8–10]. Specifically, solutions based on the use of optical modalities for 
glucose sensing include Raman spectroscopy [11–14], optical coherence tomography (OCT) 
[15,16], photoacoustic spectroscopy [17–19], optical polarimetry [20–24], infrared 
spectroscopy [25,26], and fluorescence spectroscopy [27–32]. The optical technique being 
developed by our group has been a fluorescence intensity approach based on a competitive 
binding assay of fluorescently labeled Concanavalin A (Con-A) and a competing ligand that 
can function in the complex sample of interstitial fluid [33]. 
Con-A is a lectin that binds to carbohydrate moieties found in glycoproteins, glycolipids 
and various sugars in the presence of calcium and manganese divalent cations [34,35]. As 
reported previously, Con-A can exist as a tetramer and has been used as a component of 
glucose sensitive assays, specifically with dextran [28,36–38]. The biotoxicity of Con-A has 
been extensively studied, and has been shown to pose little to no adverse health risk in use for 
in vivo sensing at low concentrations [39]. In an attempt to decrease the irreversible binding 
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 associated with the Con-A/dextran system, our group employed the use of glycosylated 
dendrimers as the competing ligand in a similar competitive assay [33]. Dendrimers are tree-
shaped, globular macromolecules that have been explored for potential uses in 
chemotherapeutics [40,41], anti-viral pharmaceuticals [42–46], and scaffolds for tissue repair 
[47,48] due to their biocompatibility. Glycosylated dendrimers have also been used as a 
coating to significantly improve the biocompatibility of carbon nanotubes [49]. By adjusting 
the size and altering the functional end-groups of the dendrimers, the effective diameter, 
molecular weight, and hydrophilicity can be varied [50–52]. Using specifically tailored 
glycosylated dendrimers, our current assay employs the use of aggregation that is induced by 
competitive binding of multivalent components, which results in a fluorescence intensity that 
correlates to glucose concentration (Fig. 1). This combined assay and the protein individually 
have been shown to be functional for several days at body temperature (37 °C) [53]. 
 
Fig. 1. This is a schematic representation of the aggregative nature used in the Con-
A/dendrimer assay. With the assay exposed to low glucose concentrations (A) the assay emits 
lower fluorescence than when the assay is exposed to high glucose concentrations (B). 
For functioning aggregative assays to be translated from the cuvette to implantable 
sensors, specifically tailored encapsulation methods which maintain the chemistry’s binding 
kinetics must be employed. Requirements for such a strategy must include the withholding of 
components throughout the sensor’s delivery and lifetime while allowing for the appropriate 
diffusion of the targeted analyte and subsequent response of the sensing chemistry. Much 
work in the field of encapsulation has been focused on the extension of drug delivery profiles. 
Concepts such as polymeric microspheres [54–56] and layer-by-layer (LbL) approaches [57–
59] have been used and reported. These microencapsulation techniques have begun to be 
altered for general sensing purposes in attempt to meet the aforementioned requirements [60]. 
For example, several groups have loaded sacrificial spherical templates (i.e. melamine 
formaldehyde and calcium carbonate) with proteins and sensing chemistry that can then be 
exposed to alternating layers of poly-electrolytes which coat the template [61–63]. These 
cores can then be dissolved freeing the chemistry within the micron-sized LbL capsule that 
can then serve as a semi-permeable membrane for sensing purposes. Advantages of this 
technique include the fine level of control for the mesh size of the capsule and the high 
synthetic reproducibility. However, future work must be done to minimize the effects of 
electrostatic binding of the sensing chemistry to the charged interior wall of the capsule [64]. 
Additionally, groups have embedded sensing chemistries within a dense matrix in an attempt 
to maintain long-term functionality. Poly-(ethylene glycol) (PEG) has been employed in this 
manner due to its proven biocompatibility and hydrophilic nature [65]. Microspheres can be 
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 created using PEG by crosslinking the individual chains via thermo-chemical or photo-
chemical initiation, resulting in a mesh of PEG chains in which chemistry can be embedded. 
The effective pore size of this mesh can be altered by varying the average molecular weight of 
the PEG and/or changing the water content within the precursor solution prior to crosslinking 
[66,67]. With these variations, the mesh size for PEG can be tailored to be suitable for sensing 
purposes. However, the sensing response of assays embedded within this mesh has been 
limited in its reversibility due to the consistent mesh within these spheres without attachment 
of the assay to the polymeric backbone [68]. 
Until now, the successful encapsulation of the Con-A/glycodendrimer glucose sensing 
assay has not been reported. Previously, our group has proposed and presented an 
encapsulation strategy combining a water-in-oil emulsion technique with the addition of sugar 
crystals to the precursor PEG solution to form assay-filled pores within the hydrogel matrix of 
the microspheres. This microporation technique was shown to be functional with the Con-
A/Dextran glucose sensitive assay – displaying a reversible response over several days [68]. 
Since microporated PEG spheres allowed competitive binding within the larger pores while 
providing for diffusion of smaller analytes due to the selectively permeable mesh, it was 
believed that similar biocompatible microporated microspheres may be candidates for housing 
the aggregative Con-A/glycodendrimer sensing assay. Work presented here explores the 
effectiveness of this technique in encapsulating the sensing chemistry with respect to its 
dynamic range, sensitivity, and reversibility. 
2. Materials and methods 
Concanavalin A (type IV), dimethyl sulfoxide (DMSO), trizma- hydrochloride (Tris-HCl), 
manganese chloride (MnCl2), sodium chloride (NaCl), D-glucose, D-mannitol, poly(ethylene 
glycol) diacrylate (PEG-DA) (Mn ~575), and light mineral oil were purchased from Sigma-
Aldrich (St. Louis, MO). In addition, 1 M hydrochloric acid (HCl), 1 M sodium hydroxide 
(NaOH), and 0.1 M phosphate buffered saline (PBS) was purchased from Sigma-Aldrich. 
Alexa Fluor 647 - succinymidyl ester was purchased from Invitrogen (Carlsbad, CA), and 
sodium bicarbonate (NaHCO3) and dextrose were purchased from Fisher Scientific 
(Waltham, MA). Calcium chloride (CaCl2) was purchased from EMD Chemicals (Gibbstown, 
NJ). Sephadex beads (G75) were purchased from Amersham Biosciences (Waukesha, WI), 
and Darocur 1173 was purchased from CIBA Specialty Chemicals (Tarrytown, NY). Distilled 
water used in experiments was collected from the Millipore filtration system at 18 MΩ 
(Billerica, MA). Glycosylated dendrimers averaging 12 glucose moieties and 12 amine 
functional groups were received from Dr. Simanek’s lab group at Texas A&M University 
using similar triazine architecture as that previously described [69]. Tris buffer used in these 
experiments was created via the formulation of 0.15 M NaCl, 0.1 M Tris-HCl, 1 mM CaCl2, 
and 1 mM MnCl2, and titrated with the appropriate aliquots of 0.1 M NaOH & 0.1 M HCl to 
adjust the pH to 7.3. 
2.1. Labeling Concanavalin A 
Con-A, the glucose receptor for the competitive binding assay, was labeled using the Amine-
Reactive Protocol via Invitrogen. Briefly, 10 mg of Con-A was dissolved in 1 mL of 0.1 M 
sodium bicarbonate buffer (pH ~8.3) and 1 mg of Alexa Fluor 647 succinymidyl ester was 
added to 100 μL DMSO. The dye/DMSO was then added to the protein solution while it was 
being stirred, and the resultant was continuously stirred for one hour at room temperature to 
complete the reaction [70]. As approximately 1/4th of the dye actually binds to the amine 
groups on the Con-A tetramers, separation was performed on a Sephadex column made of 
G75 beads that had been swelled in TRIS buffer. Inactive Con-A and free dye were collected 
while passing TRIS buffer, and active labeled Con-A was eluted by passing a 200 mg/mL 
glucose solution through the column. This final collection volume was dialyzed against TRIS 
buffer with several buffer exchanges over the course of several days to remove the glucose 
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 solution. This dialyzed fraction was concentrated by centrifugation, and the 
concentrations/labeling ratios were then determined by measuring the absorption spectra of 
the volumes. These measurements were performed by UV-VIS spectrometry indicating a 
labeling ratio of 4.7 dye molecules per Con-A tetramer. This solution was then diluted to 1.0 
mg/mL with the addition of TRIS buffer. 
2.2. Microsphere synthesis 
Two groups of microspheres, hereafter called microporated-PEG and PEG-50, were created to 
display the functionality of the microporated microspheres. PEG-50 spheres are created with 
50% water and 50% PEG, and microporated microspheres are created with pores within a 
100% PEG solution. For comparison, schematic renditions of these are displayed in Fig. 2 as 
well as that of 100% PEG solution. PEG-50 spheres have shown to be effective in allowing 
the assay to respond with limited reversibility while PEG-100 spheres have been shown to 
have limited response but high reversibility [60]. Therefore, the microporation technique aims 
to capture the advantages of both by creating larger assay-filled pores within the tighter mesh 
of the PEG-100 spheres. 
To create the porogen for the microporated PEG microspheres, 200 μL of AF-647 Con-A 
stock solution, 100 μL of G2-Dendrimer stock solution, 300 μL of PBS, and 20 mg of 
mannitol were added together. This precursor solution was mixed well, and then lyophilized 
overnight. In order to make the precursor polymeric solution for the microporation technique, 
10 mg of the lyophilized sample was added to 1 mL PEG-DA (MW 575) and 10 μL Darocur. 
This solution was stirred to break up the lyophilized crystals into smaller particles. To make 
the polymeric precursor for the PEG-50 microspheres, 500 μL PEG-DA (MW 575), 100 μL 
ConA, 50 μL G2 Dendrimer, 350 μL TRIS buffer, and 10 μL Darocur were added together 
and mixed well. 
A water-in-oil emulsion technique was implemented by adding 50 mL of light mineral oil 
to a 100 mL beaker. This solution was stirred via a magnetic stir plate, rotating at 
approximately 500 rpm. Under these conditions, the polymeric precursor was pipette into the 
beaker and allowed to spin for 15 seconds to create a fairly homogenous set of spheres. An 
ultraviolet light source (EFOS Ultracure 100SS Plus) at a wavelength of 365 nm was shone 
incident upon the beaker from a probe at 20 W/cm2 for 2.5 seconds to sufficiently cause the 
cross-linking via free-radical photo-initiation. Spheres were removed from the oil bath and 
vigorously rinsed with TRIS buffer via several buffer exchanges, and then added to a final 
solution of TRIS buffer. Spheres were stored at 4 ̊C after synthesis. 
 
Fig. 2. This represents the mesh/pore sizes associated with various synthesized spheres. A 
represents PEG50 spheres (50% water, 50% PEG precursor) and has a very loose mesh. B 
represents PEG100 spheres (100% PEG precursor) and has a tight mesh. C represents 
microporated spheres (100% PEG with mannitol) that have large pores within the tighter mesh 
seen in B. These pores allow the sensing aggregation previously described. 
#143121 - $15.00 USD Received 23 Feb 2011; revised 25 Mar 2011; accepted 12 Apr 2011; published 18 Apr 2011
(C) 2011 OSA 1 May 2011 / Vol. 2,  No. 5 / BIOMEDICAL OPTICS EXPRESS  1249
 2.3. Imaging spheres 
To examine the average size of these particles, a bright-field microscopy technique was 
performed using a Leica DMLM microscope by adding a small volume of spheres on the 
surface of a microscope slide. To calculate the average diameter for each group of 
microspheres, ten images were captured by randomly translating the x-y motorized stage and 
focusing on the spheres within the image plane via a 10x objective. The diameters were 
calculated for each in-focus sphere that was taken, and the average diameter and standard 
deviation for each set was found. 
The poration within the PEG microspheres was examined through the use of a confocal 
fluorescence microscope by taking slices of the collected fluorescence through the depth of 
the sphere. This was performed using a Leica TCS SP5 Confocal Microscope. For these 
experiments, a HeNe 632.8 nm laser was used at 4.5 mW with a 73.7 um pinhole and a 10x, 
0.3 NA, dry objective. Images were taken without averaging and the resulting Z-step size was 
2.383 μm with a 512 x 512 pixel resolution for the frame. This procedure was performed for 
both groups of the synthesized microspheres. Since these microspheres were comprised of a 
hydrogel material that largely consists of water, the refractive index of these spheres was 
approximately 1.37 [71]. These spheres were immersed in TRIS buffer (n = 1.33) for confocal 
scans. Therefore, the shape of the sphere did not display a significant distortion of the image 
as the index was somewhat matched. 
2.4. Optical set up & fluorescent response to glucose 
Fluorescent measurements with regards to leaching were performed on a commercially 
available spectrofluorometer system (Make: Photon Technology International, Model: Model 
L-201M Source, MP-1 Sample Compartment, and Model 814 Analog/Photon-Counting 
Photomultiplier Detector). In emission scan mode, the incident light was set to 633 nm and the 
emission monochromator was scanned from 650 nm to 710 nm with 1 nm steps and 1 second 
integration times. Fluorescent measurements of the sensing spheres with regard to response 
and long-term reversibility were taken with a custom-designed 90 degree fluorescence optical 
set up, represented in Fig. 3. A cuvette holder held the micro-cuvette containing the sensing 
spheres, and a 5 mW, HeNe 632.8 nm laser was made incident normal to its face. Due to the 
slight mismatch of refractive index between the spheres (1.37) and the buffer (1.33), there 
were multiple scattering events. Given the 1 cm pathlength of the cuvette, a 1 mm beam 
width, and scatter due to the packed spheres, the sampling volume is approximately 25 uL. 
This corresponded to approximately 250 spheres within that sampling volume. At 90 degrees,  
 
 
Fig. 3. This is a representation of the optical set up for 90-degree fluorescence measurements of 
sensing microspheres with a CCD Spectrometer and a HeNe 632.8 laser. 
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 a Roper Scientific SpectraPro 150 spectrometer was placed with a fixed slit width, and a 650 
nm long-pass, emission filter was used to eliminate stray laser light. The integration time of 
the system was 500 milliseconds to avoid saturation of the signal, and the grating had a blaze 
wavelength at 750 nm with 1200 grooves/mm. For collection purposes, the spectrometer was 
centered at 690 nm, collecting counts from 647 nm to 727 nm. This was performed to further 
minimize saturating the detector with scattered light from the source and in order to 
sufficiently measure the peak of the Alexa Fluor 647 emission at approximately 670 nm. The 
fluorescent intensity value used in all subsequent data analysis was the maximum value of the 
fluorophore emission for each spectrum collected. 
2.5. Titration 
For titration measurements, 500 μL of microporated microspheres were packed within a 
microcuvette and 2 mL of TRIS buffer were added. These microcuvettes were used to 
minimize the amount of spheres used. Highly concentrated, low volume aliquots of glucose 
were then added to the cuvette to make the surrounding solution increase in glucose 
concentration. This addition was performed without perturbing the settled spheres to assure 
adequate comparison. Sufficient time was given to allow for the diffusion of varying glucose 
concentrations into the spheres and for the response of the assay to achieve steady state. Three 
runs were performed for the microporated spheres and triplicate data was recorded for each 
run. The refractive index change between 0 mg/dL and 6000 mg/dL glucose levels have been 
shown to increase from 1.333 to 1.34 [72]. As the physiological glucose concentration are an 
order of magnitude less than this step change, the change in refractive index should be 
negligible when compared to the fluorescent response from the competitive binding 
chemistry. 
In addition, the titration was performed on free assay in solution. A sensing assay was 
formulated in an attempt to mimic those concentrations and ratios seen within the 
microporated spheres for proper comparison. Specifically, 2 mL of TRIS buffer and 100 μL of 
1 mg/mL Con-A was added to the cuvette. 50 μL of glycodendrimer was then added and 
given 1 hour to equilibrate and fluorescent measurements were taken resulting in an assay 
with 450 nM Con-A & 2.3 uM dendrimer. Aliquots of glucose were added to the system 
making glucose concentrations in step-wise fashion up to 1000 mg/dL. Steady state 
measurements were taken upon each addition after giving time for the system to equilibrate. 
Three runs were performed for the titration in free solution and triplicate data was recorded 
for each run. 
2.6. Leaching 
For the leaching experiments, 500 μL of both groups of microspheres that had not been 
exposed to glucose were packed in microcuvettes with the addition of 2 mL of TRIS buffer 
and given time to settle. Triplicate fluorescence spectra were then taken for baseline, 0 mg/dL 
glucose, measurements. Equivalent dilution factors were performed on each cuvette by adding 
60 uL aliquots of 200 mg/mL glucose solutions to the settled spheres without perturbation to 
achieve glucose saturated solutions (600 mg/dL). To allow for the maximum response and any 
subsequent leaching, the spheres were given twenty-four hours upon the addition of glucose 
prior to triplicate fluorescence spectra being taken. Supernatant was then collected from the 
microcuvette and triplicate fluorescent spectra were taken to quantify the amount of leaching, 
if any, of the fluorescently labeled Con-A from within the microspheres. 
2.7. Reversibility 
The reversibility of the system was tested by packing 500 μL of microporated-PEG into a 
microcuvette and adding 2 mL of TRIS buffer. These spheres were allowed to settle, and 
triplicate baseline fluorescent readings were taken for each. A highly concentrated aliquot of 
glucose was then added to make the resulting solution 300 mg/dL. Fluorescent readings were 
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 taken again six hours after the glucose was added to the cuvette to be assured the system was 
at steady-state. The remaining buffer in the microcuvette was then exchanged 4 times that 
evening, and exchanged 3 times the following morning to assure that the glucose 
concentration was effectively zero. This entire process was repeated for fourteen consecutive 
days. 
3. Results & discussion 
3.1. Bright field microscopy examples & size 
Per the technique previously described, the average diameter of the microporated spheres was 
determined to be 545 μm with a standard deviation of 242 um. In comparison, the average 
diameter of the PEG-50 spheres was determined to be 476 um with a standard deviation of 
174 um. As the ultimate application for these spheres is to be minimally invasive 
subcutaneous interstitial glucose sensors, they must be capable of being embedded 
interstitially. Therefore, future work will focus on reducing the average diameter by 
decreasing the size of the emulsified PEG droplets. However, for comparison purposes in this 
study the two sets of spheres were roughly the same size on average. 
3.2. Poration 
The crux of this work depends on the ability for pockets to be created that allow the Con-
A/glycodendrimer sensing assay to be held within a tight polymeric mesh but also allow for 
diffusion of the glucose analyte and room for the aggregative assay to respond to the glucose 
concentration. From the fluorescence confocal microscopy images, the differences between 
PEG-50 spheres and microporated spheres are visualized. With a step size in the Z direction 
of 2.383 microns, these images show a slice through the interior of the spheres which display 
the fluorescent Con-A particles. For the microporated microspheres, the fluorescence is 
localized within striated pockets which are the residual imprint of sugar crystals that had since 
been dissolved. The average volume fraction of these pores is approximately 1% when 
accounting for the v/v% ratio between mannitol within the PEG precursor. In comparison, 
there is no such localization for PEG-50 spheres (Fig. 4). PEG-50 spheres do show a relatively  
 
 
Fig. 4. These are hybrid images of false-colored confocal fluorescence slices overlaid onto 
bright-field images of the microspheres. The fluorescence displays the location of the labeled 
Con-A within the hydrogel, and it shows the differences of the pore distribution between 
PEG50 microspheres (A) and microporated microspheres (B). The large pores in B allow for 
the sensing mechanism to function effectively while maintaining reversibility by preventing 
leaching. The reference bar is 100 μm in length. 
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 homogenous distribution of fluorescence; however, this distribution is a result of the non-
localized withholding of sensing chemistry. Ultimately, it may be beneficial for the 
microporated microspheres to have a more homogenous distribution of size and distribution of 
pockets since a disperse population of sensing spheres with regard to these variables could 
result in a response that is dependent on which spheres are being interrogated. Future work 
will be done to minimize the variability by increasing the porogen to PEG ratio, increasing the 
speed of the homogenizer, adding surfactant to the precursor, and using a 
centrifugation/filtration system to retrieve the desired sphere-size. 
3.3. Titration 
Typically, the sensing response for an assay is inhibited by the specific attachment strategy 
due to the manipulation of the free binding kinetics. For an aggregative assay like the Con-
A/glycodendrimer system described here, such strategies would result in prohibiting any 
response by preventing the mechanism, aggregation, to take place. Since this strategy does not 
purposely employ the use of a covalent/ionic attachment, and instead allows the chemistry to 
remain free within pores it was hoped that the sensing response would be present and similar 
to that seen in solution. Figure 5 displays the titration response to monotonic increasing 
concentrations of glucose for microporated microspheres. The microporated response is 
relatively linear from 50 to 200 mg/dL with a sensitivity of 1.3% per 10 mg/dL, and the 
response at 200 mg/dL is at 75% of the total response of the sensor. For comparison, Fig. 6 
displays the fluorescent response for the sensing assay in solution across physiological 
concentrations of glucose as compared to the microporated response – displaying a linear 
response through 500 mg/dL of glucose and a sensitivity of 1.8% per 10 mg/dL. Above 500 
mg/dL, the sensitivity decreases to approximately 0.4% per 10 mg/dL. In free solution, the 
sensing chemistry is at approximately 35% of the linear dynamic response at 200 mg/dL. The 
microporated sensing spheres do show a slightly greater sensitivity through the hypoglycemic 
range (0-100 mg/dL); however, there is an overall decrease in the dynamic range and  
 
 
Fig. 5. Titration response to glucose: Glucose was titrated into a cuvette containing 
microporated microspheres. The system was given time to be at steady-state prior to readings. 
The intensity of the fluorescence is compared to the initial fluorescence seen at 0 mg/dL 
glucose concentration. Error bars depict the standard deviation through three separate titration 
runs. 
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 fluorescent signal. A possible explanation for this decrease includes the variable loading of 
sensing components since the ratio of free/bound competing ligand is dependent on the 
concentration of the receptor and competing ligand for steady-state glucose concentrations. 
Therefore, any change in either the Con-A or glycodendrimer concentration within the pores 
will shift the response in a manner similar to that observed. This shift can also be attributed to 
the confinement of the aggregative sensing assay within pores, a process that can theoretically 
shift the distribution of aggregates to favor smaller particles in comparison to free solution 
with a given glucose concentration because of entropy requirements and steric hindrances 
presented by the pores. As the fluorescent response is dependent on the extent of competitive 
binding, this shift in aggregation can shift the response to mimic that seen at higher glucose 
concentrations of the assay in free solution. 
The standard deviation seen in the titration response of the microporated spheres was also 
higher than that for the free assay. This can be attributed to the variation which was seen in 
the poration of the spheres. The rinsing of spheres required to eliminate the glucose within the 
buffer between runs may have resulted in a different subset of spheres being interrogated each 
time that ultimately could add noise to the system. As previously mentioned, the dynamic 
range of the assay is a function of the aggregation associated with competitive binding 
between the Con-A and glycosylated dendrimer. Therefore, the fluorescent response it is 
primarily dependent on the equilibrated glucose concentration. However, since the sensing 
chemistry is aggregative is nature, the dynamic range would be dependent on the size of the 
pores that contain the assay if they limited the extent of aggregation. The dynamic range of 
the sphere size should be independent of the individual sphere size and porosity, given that 
they allow for the appropriate size for individual pores. 
The response time of the sensing chemistry within the spheres is primarily dependent on 
the diffusivity of hydrogel, the size of the spheres, and the porosity (volume fraction) of the 
spheres for whatever system they are placed in. Specifically, higher diffusivities should 
decrease response time for equilibrium, larger spheres should increase diffusion distances and 
increase response time, and higher porosity should decrease diffusion distances and decrease 
response time. 
 
Fig. 6. Comparison of Response: This is the normalized fluorescent response of the assay in 
free solution compared to the normalized fluorescent response of the assay within microporated 
microspheres. 
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 3.4. Leaching 
The quantification of the leaching from within the microporated microspheres and PEG-50 
microspheres is displayed by Fig. 7. Upon 24 hours of exposure to highly concentrated 
volumes of glucose (600 mg/dL), the supernatant showed insignificant values of fluorescence 
from the fluorescently labeled Con-A for microporated microspheres indicating that no 
leaching had occurred. In comparison, the plot of the fluorescence from the supernatant for 
the PEG-50 microspheres shows approximately 20% of the original fluorescence signal from 
the fluorescently labeled Con-A and confirms the problematic leaching associated with the 
PEG-50 polymeric mesh for encapsulation purposes. For these PEG-50 microspheres, the 
aggregates are sufficiently large to remain entrapped within the polymeric crosslinks at low 
concentrations of glucose. However, upon the addition of glucose, Con A competitively binds 
to the analyte rather than the glycodendrimer – decreasing the size of the aggregates. The 
fluorescently labeled Con-A chemistry attached to the glucose as well as the free glycosylated 
dendrimer is then capable of diffusing outwardly, into the supernatant. In contrast, the 100% 
PEG around the pores of the microporated microspheres seen via confocal microscopy is 
capable of withholding the assay throughout physiological concentrations of glucose due to 
the tighter mesh. As previously described, the long-term application of any sensing scheme 
requires an effective encapsulation/attachment method which disallows the undesirable 
release of key chemistry components. This leaching is effectively eliminated via the 
microporation technique and provides long-term functionality for the aggregative assay. 
 
Fig. 7. Leaching Studies: Steady state fluorescent scans were taken for microporated and 
PEG50 microspheres at 0 mg/dL and 600 mg/dL. The supernatant was removed and scanned to 
determine if labeled Con-A leached out of the matrix. Fluorescence data is plotted relative to 
the initial 0 mg/dL scan. Error bars depict the standard deviation of the recorded measurements. 
3.5. Reversibility 
Fluorescent opto-chemical sensors often lose their functionality as a result of irreversible 
binding of the sensing components, photobleaching of the fluorophore, leaching of the 
chemistry, and/or the denaturing of the tertiary structure for the binding receptor [73,74]. In an 
attempt to address part of this potential problem with reversibility, glycosylated dendrimer 
was used in this system to avoid the increased binding affinity from a tetrameric unit of Con-
A binding to multiple sites, such as what may occur for a long chain like dextran, and by 
using Alexa Fluor 647 which is more resistant than other fluorophores, such as the rhodamine 
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 dyes, to photobleaching. As displayed in Fig. 8, the microporated microsphere sensor is 
shown to respond to cycling from 0 to 300 mg/dL glucose concentration over a duration of 
fourteen days. The key result is that there is reversibility with no drop off toward the end of 
the two weeks, a result that has not been previously displayed. In terms of absolute count, the 
signal from the microporated spheres show a declining trend as displayed in Fig. 8a. The 
majority of the aforementioned reasons for such a loss in functionality should be exponential 
in nature, but this absolute response does not appear to have a true exponential decay. This 
could be due to the combination of the effects on the aggregative assay. However, the relative 
increase from 0 mg/dL to 300 mg/dL each day shows no such trend as displayed in Fig. 8b. 
Therefore, a ratiometric sensing scheme using two fluorophores could be employed to 
maintain long-term functionality and reversibility. The relative results do show fluctuations in 
the response from day to day; however, as previously mentioned, we believe the variability in 
the relative readings between days is a result of polydispersity of the spheres in both the size 
and poration. Nonetheless, the data convincingly shows that microporated microspheres can 
effectively allow the sensing assay to remain functional and reversible to varying glucose 
concentrations through fourteen days at ambient conditions. 
 
Fig. 8. Reversibility: Steady state fluorescent scans were taken each day at 0 mg/dL and 300 
mg/dL glucose concentrations for a set of microporated microspheres. The absolute normalized 
fluorescent counts (a) and the relative daily increase fluorescence (b) are plotted for 0 mg/dL 
and 300 mg/dL for important days. Note that while there is a monotonic decrease in the 
absolute fluorescent intensity seen in (a), the relative fluorescent response (b) remains stable 
over this same time period. Error bars depict the standard deviation of the three recordings 
4. Conclusion 
In this work, the Con A/glycodendrimer glucose sensitive assay is shown, for the first time, to 
remain functional to varying glucose concentrations within polymeric microspheres. A 
microporation technique is used in which assay-filled pores are created within a polymeric 
mesh that allows the diffusion of glucose to the interior pockets while withholding the 
chemistry from outwardly diffusing throughout the competitive binding response. In addition, 
the microporation synthesis was shown to be advantageous for the aggregative sensing 
chemistry for several reasons: (1) it does not require the addition of powerful solvents to 
dissolve the porogen that could disrupt the tertiary structure of the protein, (2) the PEG 
hydrogel is hydrophilic and biocompatible which allows it to ultimately be implanted within 
the dermal layers of the tissue, and (3) the cross-linking between PEG chains is covalent 
which is not susceptible to electrostatic binding of the sensing chemistry to the inner surface. 
As a result, the sensing spheres were shown to be responsive to glucose with a sensitivity of 
1.3% per 10 mg/dL glucose from 50 to 200 mg/dL. In addition, because of the tight mesh 
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 surrounding the pores, there was shown to be effectively no leaching of the fluorescently 
labeled Con A from within the microporated microspheres. 
Ultimately, for these microporated Con A/glycodendrimer sensing spheres to serve as 
ideal candidates for minimally invasive sensors for diabetics, in the future work several 
variables remain to be optimized, including; decreasing the response time by increasing the 
mesh size of the crosslinked PEG, making the pore-to-microsphere size ratio more 
homogeneous, and decreasing the overall size of the spheres. 
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